Our Work

Learn about Ryniant Sciences' subsidiaries that provide an innovative, AI, & tech driven approach to biotech research and therapeutics.

NeuroLuma

NeuroLuma is a subsidiary of Ryniant Sciences focused on developing AI-driven therapies for neurodegenerative and neurological diseases. Powered by a specialized implementation of the Ominor Platform, NeuroLuma accelerates the discovery of targeted treatments for conditions like Alzheimer’s, Parkinson’s, and rare brain disorders, combining precision medicine with advanced molecular screening.

CutisLuma

CutisLuma is a Ryniant Sciences subsidiary dedicated to developing advanced treatments for skin diseases and rare dermatological conditions. Using the Ominor Platform, CutisLuma leverages AI to identify safe, effective therapies for disorders like psoriasis, eczema, and genetic skin syndromes, accelerating innovation in dermatology.

Calrivis

Calrivis is a subsidiary of Ryniant Sciences specializing in AI-powered medical diagnostics. Its flagship product, the Calrivis Alpha Z1, uses advanced deep learning to detect brain tumors from MRI scans with high accuracy, enabling earlier diagnosis and improving clinical decision-making in neurology and oncology.

RarusLuma

RarusLuma is a Ryniant Sciences subsidiary focused on developing therapies for rare and neglected diseases. Leveraging the Ominor Platform, RarusLuma uses AI to accelerate the discovery of treatments for conditions that lack commercial incentives, ensuring that life-saving innovations reach underserved patient populations.